From http://www.oktoophtho.com/

Ophthalmology Times Details Successful Use of AmbioDry for Pterygium Surgery

COSTA MESA, California - 15 October 2003 - On September 15th 2003, Ophthalmology Times, through an interview with world-renown Dr. Arun Gulani, detailed the successful use of AmbioDry for pterygium surgery in the article titled, Amniotic Membrane Lowers Chance of Pterygium Recurrence.

Pterygium is recognized as one of the oldest ocular pathologies. In the past, multiple and varied approaches and techniques have been employed by ophthalmologists throughout the world for the treatment of pterygium. The recent availability of AmbioDry Dehydrated Amniotic Membrane Allografts for pterygium surgery has provided surgeons with better results that traditional therapies.

The article states: "The chances of pterygium recurrence can be decreased by removing the entire pterygium.. In the cases of extensive excision, amniotic membrane transplantation seems to provide excellent results, according to Arun Gulani, M.D."

The article further details Dr. Gulani's unique, passionate methodology for the treatment of pterygium, his aggressive approach to growth excision, and his innovative surgical technique in the placement of the AmbioDry tissue graft. Arun Gulani, M.D. is the chief of cornea external disease and director of refractive surgery at the University of Florida, Jacksonville.

"Our main goal with the AmbioDry technology has been, and continues to be, to replace the time consuming techniques traditionally employed by ophthalmologists for the treatment of pterygium ", stated Erich Ziegler, President of OKTO Ophtho. "Dr. Gulani's experience in the treatment of pterygium is unrivaled. His successful, innovative approach to the disease, through expansive excision and the placement of AmbioDryT, improves patient outcomes and surgeon productivity."

About OKTO

Founded in 2000, OKTO Ophtho develops and commercializes specialized, leading-edge surgical technologies for eye surgery. OKTO's purpose is to develop surgical solutions that improve the quality of life for patients, elevate the performance and productivity of eye care professionals, and lower costs to the provider.OKTO currently holds leadership positions with surgical devices for oculoplastic surgeries and bio-implant technologies for ocular surface/ophthalmic reconstructive surgeries.